This clinical trial is focused on studying the effectiveness of a vaccine called Apexxnar, which is a 20-valent pneumococcal conjugate vaccine. This vaccine is designed to protect against a type of lung infection known as community-acquired pneumonia in adults aged 65 and older. Community-acquired pneumonia is a lung infection that people can get outside of a hospital setting, and it can be confirmed through imaging tests like X-rays.
The purpose of the study is to determine how well the Apexxnar vaccine works in preventing pneumonia caused by specific types of bacteria that the vaccine targets. Participants in the study will receive either the vaccine or a placebo. The study will monitor participants to see if they develop pneumonia and will use this information to assess the vaccine’s effectiveness. The vaccine is given as an injection into the muscle, similar to a flu shot.
Throughout the study, participants will be observed for any signs of pneumonia, such as fever, cough, or difficulty breathing. The study will also consider factors like age, sex, and previous vaccinations to understand how these might affect the vaccine’s performance. The trial is expected to continue until 2027, providing valuable data on the vaccine’s ability to prevent pneumonia in older adults.
Spain 
